Zięba Agata, Kędzierska Ewa, Jastrzębski Michał K, Karcz Tadeusz, Olejarz-Maciej Agnieszka, Sumara Agata, Laitinen Tuomo, Wróbel Tomasz M, Fornal Emilia, Castro Marián, Kaczor Agnieszka A
Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Laboratory, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki St., 20093 Lublin, Poland.
Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki St., 20093 Lublin, Poland.
Molecules. 2025 May 14;30(10):2165. doi: 10.3390/molecules30102165.
Many drug discovery efforts have identified potentially promising molecules; however, a common limitation of these reports is the lack of further experimental confirmation of pharmacokinetic properties and behavioral effects of discovered compounds. In this study, we aim to address this limitation. Therefore, we build on our previous virtual screening campaign by synthesizing, analyzing in silico, and evaluating experimentally the SERAAK1 compound, which was initially identified as a ligand for 5-HT, 5-HT, and D receptors. Through these investigations, we discovered that SERAAK1 binds to the orthosteric pocket of the 5-HT receptor in a similar mechanism to that known for marketed antipsychotic medications. Molecular dynamics simulations revealed that the SERAAK1 compound remains stable in the orthosteric binding pocket of the 5-HT receptor. The determination of the ADMET parameters indicated the directions for further optimization of the compounds. In vivo studies demonstrated the anxiolytic and antidepressant properties of the SERAAK1 compound.
许多药物研发工作已经确定了具有潜在前景的分子;然而,这些报告的一个共同局限性是缺乏对所发现化合物的药代动力学特性和行为效应的进一步实验证实。在本研究中,我们旨在解决这一局限性。因此,我们基于之前的虚拟筛选活动,通过合成、计算机模拟分析以及对最初被鉴定为5-羟色胺(5-HT)、5-羟色胺(5-HT)和多巴胺(D)受体配体的SERAAK1化合物进行实验评估。通过这些研究,我们发现SERAAK1以与市售抗精神病药物已知机制类似的方式结合到5-HT受体的正构口袋中。分子动力学模拟表明,SERAAK1化合物在5-HT受体的正构结合口袋中保持稳定。ADMET参数的测定为化合物的进一步优化指明了方向。体内研究证明了SERAAK1化合物的抗焦虑和抗抑郁特性。